196 related articles for article (PubMed ID: 30280600)
1. Arginine reprogramming in ADPKD results in arginine-dependent cystogenesis.
Trott JF; Hwang VJ; Ishimaru T; Chmiel KJ; Zhou JX; Shim K; Stewart BJ; Mahjoub MR; Jen KY; Barupal DK; Li X; Weiss RH
Am J Physiol Renal Physiol; 2018 Dec; 315(6):F1855-F1868. PubMed ID: 30280600
[TBL] [Abstract][Full Text] [Related]
2. Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease.
Hopp K; Kleczko EK; Gitomer BY; Chonchol M; Klawitter J; Christians U; Klawitter J
Am J Physiol Renal Physiol; 2022 Mar; 322(3):F258-F267. PubMed ID: 35037466
[TBL] [Abstract][Full Text] [Related]
3. Parallel microarray profiling identifies ErbB4 as a determinant of cyst growth in ADPKD and a prognostic biomarker for disease progression.
Streets AJ; Magayr TA; Huang L; Vergoz L; Rossetti S; Simms RJ; Harris PC; Peters DJ; Ong AC
Am J Physiol Renal Physiol; 2017 Apr; 312(4):F577-F588. PubMed ID: 28077374
[TBL] [Abstract][Full Text] [Related]
4. Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model.
Leonhard WN; van der Wal A; Novalic Z; Kunnen SJ; Gansevoort RT; Breuning MH; de Heer E; Peters DJ
Am J Physiol Renal Physiol; 2011 May; 300(5):F1193-202. PubMed ID: 21345977
[TBL] [Abstract][Full Text] [Related]
5. Attenuation of accelerated renal cystogenesis in Pkd1 mice by renin-angiotensin system blockade.
Fitzgibbon WR; Dang Y; Bunni MA; Baicu CF; Zile MR; Mullick AE; Saigusa T
Am J Physiol Renal Physiol; 2018 Feb; 314(2):F210-F218. PubMed ID: 29021226
[TBL] [Abstract][Full Text] [Related]
6. Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells.
de Stephanis L; Bonon A; Varani K; Lanza G; Gafà R; Pinton P; Pema M; Somlo S; Boletta A; Aguiari G
Clin Exp Nephrol; 2017 Apr; 21(2):203-211. PubMed ID: 27278932
[TBL] [Abstract][Full Text] [Related]
7. Three-dimensional in vitro models answer the right questions in ADPKD cystogenesis.
Dixon EE; Woodward OM
Am J Physiol Renal Physiol; 2018 Aug; 315(2):F332-F335. PubMed ID: 29693448
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis.
Li A; Fan S; Xu Y; Meng J; Shen X; Mao J; Zhang L; Zhang X; Moeckel G; Wu D; Wu G; Liang C
J Cell Mol Med; 2017 Aug; 21(8):1619-1635. PubMed ID: 28244683
[TBL] [Abstract][Full Text] [Related]
9. STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease.
Fragiadaki M; Lannoy M; Themanns M; Maurer B; Leonhard WN; Peters DJ; Moriggl R; Ong AC
Kidney Int; 2017 Mar; 91(3):575-586. PubMed ID: 28104302
[TBL] [Abstract][Full Text] [Related]
10. Prostaglandin E(2) mediates proliferation and chloride secretion in ADPKD cystic renal epithelia.
Liu Y; Rajagopal M; Lee K; Battini L; Flores D; Gusella GL; Pao AC; Rohatgi R
Am J Physiol Renal Physiol; 2012 Nov; 303(10):F1425-34. PubMed ID: 22933297
[TBL] [Abstract][Full Text] [Related]
11. Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease.
Hwang VJ; Zhou X; Chen X; Trott J; Abu Aboud O; Shim K; Dionne LK; Chmiel KJ; Senapedis W; Baloglu E; Mahjoub MR; Li X; Weiss RH
Kidney Int; 2017 Oct; 92(4):922-933. PubMed ID: 28545714
[TBL] [Abstract][Full Text] [Related]
12. Possible role of the mitochondrial genome in the pathogenesis of autosomal dominant polycystic kidney disease.
Saravanabavan S; Rangan GK
Nephrology (Carlton); 2021 Nov; 26(11):920-930. PubMed ID: 34331378
[TBL] [Abstract][Full Text] [Related]
13. Renal expression of JAK2 is high in polycystic kidney disease and its inhibition reduces cystogenesis.
Patera F; Cudzich-Madry A; Huang Z; Fragiadaki M
Sci Rep; 2019 Mar; 9(1):4491. PubMed ID: 30872773
[TBL] [Abstract][Full Text] [Related]
14. Generation of special autosomal dominant polycystic kidney disease iPSCs with the capability of functional kidney-like cell differentiation.
Huang J; Zhou S; Niu X; Hu B; Li Q; Zhang F; Zhang X; Cai X; Lou Y; Liu F; Xu C; Wang Y
Stem Cell Res Ther; 2017 Sep; 8(1):196. PubMed ID: 28927462
[TBL] [Abstract][Full Text] [Related]
15. The regulatory 1α subunit of protein kinase A modulates renal cystogenesis.
Ye H; Wang X; Constans MM; Sussman CR; Chebib FT; Irazabal MV; Young WF; Harris PC; Kirschner LS; Torres VE
Am J Physiol Renal Physiol; 2017 Sep; 313(3):F677-F686. PubMed ID: 28615245
[TBL] [Abstract][Full Text] [Related]
16. TAZ/Wnt-β-catenin/c-MYC axis regulates cystogenesis in polycystic kidney disease.
Lee EJ; Seo E; Kim JW; Nam SA; Lee JY; Jun J; Oh S; Park M; Jho EH; Yoo KH; Park JH; Kim YK
Proc Natl Acad Sci U S A; 2020 Nov; 117(46):29001-29012. PubMed ID: 33122431
[TBL] [Abstract][Full Text] [Related]
17. PKD2 deficiency suppresses amino acid biosynthesis in ADPKD by impairing the PERK-TBL2-eIF2ɑ-ATF4 pathway.
Zhou X; Xiong H; Lu Y; Geng M; Lu Y; Zhang L; Zhu X
Biochem Biophys Res Commun; 2021 Jul; 561():73-79. PubMed ID: 34015761
[TBL] [Abstract][Full Text] [Related]
18. Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.
Soomro I; Sun Y; Li Z; Diggs L; Hatzivassiliou G; Thomas AG; Rais R; Parker SJ; Slusher BS; Kimmelman AC; Somlo S; Skolnik EY
Nephrol Dial Transplant; 2018 Aug; 33(8):1343-1353. PubMed ID: 29420817
[TBL] [Abstract][Full Text] [Related]
19. Activation of P-TEFb by cAMP-PKA signaling in autosomal dominant polycystic kidney disease.
Sun Y; Liu Z; Cao X; Lu Y; Mi Z; He C; Liu J; Zheng Z; Li MJ; Li T; Xu D; Wu M; Cao Y; Li Y; Yang B; Mei C; Zhang L; Chen Y
Sci Adv; 2019 Jun; 5(6):eaaw3593. PubMed ID: 31183407
[TBL] [Abstract][Full Text] [Related]
20. Regulation of ciliary trafficking of polycystin-2 and the pathogenesis of autosomal dominant polycystic kidney disease.
Cai Y; Tang Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Feb; 35(2):93-9. PubMed ID: 20197605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
